Takeda Pharmaceutical, Affymax Conclude Licensing Agreement for Hematide, Renal/Malignant Anemia Treatment Agent.Tokyo, Japan, Feb 14, 2006 - (JCN) - Takeda Pharmaceutical announced on February 13 that it has entered into an exclusive agreement with Affymax for Hematide, Affymax's proprietary agent indicated for the treatment of renal and malignant anemia malignant anemia n. . See pernicious anemia. Under the agreement terms, Takeda will be able to exclusively develop and market the agent in Japan. In the meantime, Takeda will make an upfront payment of $17 million as well as purchasing Affymax's shares for $10 million. Further, Takeda will make milestone payments and royalties to Affymax upon successful development and commercialization of the agent. Hematide is a synthetic peptide erythropoiesis e·ryth  ro·poi·et ic (- t-stimulating agent that has a property to increase the number of erythrocytes basophilic erythrocyte an abnormal erythrocyte that takes basic stains, as seen in basophilia. hypochromic erythrocyte one that contains less than normal concentration of hemoglobin and as a result appears paler than normal; it is usually also microcytic. normochromic erythrocyte one of normal color with a normal concentration of hemoglobin. (red blood cells). Currently, Affymax is conducting a phase II clinical trial of the agent for the treatment of renal and malignant anemia. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion